SCHEMBL18542136

SCHEMBL18542136

CCCCCCCC(C)(CCCCCCC)c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.41
HDAC1 Q13547 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
CNR2 P34972 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HDAC3 O15379 1/20 0.33
CNR1 P21554 2/20 0.33
TNNC1 P63316 5/20 0.33
S1PR1 P21453 2/20 0.33
SGPL1 O95470 1/20 0.33
S1PR4 O95977 1/20 0.33
GPR183 P32249 1/20 0.33
CERS2 Q96G23 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9557316 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL21191577 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL19424088 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL9557621 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL18542125 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL19204390 1.00 ESR1 (0.41) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL18949946 0.98 ESR1 (0.40) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL21191853 0.97 ESR1 (0.42) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL9609037 0.97 ESR1 (0.42) ESR1HDAC1HDAC11HDAC8HDAC6
SCHEMBL14406535 0.97 ESR1 (0.42) ESR1HDAC1HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER CITY OF HOPE 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050922-A2 HDAC8 INHIBITORS FOR TREATING CANCER HDAC8, HDAC1, HDAC7 ESR1 2652/4885HDAC1 2/4885HDAC11 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.